Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Nexsen Enters into Molecular GBS Diagnostic Joint Venture with FlashDx Shenzhen
Nexsen to form a 50:50 GBS diagnostic JV with FlashDx Shenzhen, targeting FDA 510(k) and EU IVDR clearance and APAC market entry.
Latest Stories — SECTOR DESK
BCAL Diagnostic Commences Phased Australian Rollout of Avantect Multi-Cancer Blood Test
BCAL Diagnostics begins phased Australian rollout of Avantect Multi-Cancer blood test, expanding early detection across NSW, Victoria and beyond.
Genetic Signatures and Microba Life Sciences Set Commercial Terms for Merger
Genetic Signatures and Microba agree all-scrip merger; MAP holders to own ~67% of the combined group at 0.654 GSS per MAP share; GSS remains ASX-listed.
Nyrada Raises Fresh Capital to Fund Xolatryp Phase IIa And Pipeline Expansion
Nyrada raises A$12m via placement to fund Xolatryp Phase IIa PROTECT-MI and pipeline expansion; targets a further A$2m via SPP, with board participation.
Memphasys Secures Exclusive Distribution Agreement with INVIDO LAB for Felix System
Memphasys nets exclusive Felix System deal with INVIDO LAB in Czech Republic, Slovakia, Kazakhstan; €416k min purchases, unlocking recurring cartridge revenue.
AdAlta Validates Commercial Viability of IRO Manufacturing Strategy with Oribiotech Deal
AdAlta's IRO platform earns commercial validation as Oribiotech inks a 10-year, up to US$120m deal to manufacture a marketed cell therapy in APAC.
Prescient Therapeutics Hits Enrolment Threshold for PTX-100 Phase 2a Trial Review
Prescient Therapeutics hits enrolment milestone: PTX-100 Phase 2a reaches 20 evaluable patients; first Dose Optimisation Committee review in December 2026.
Resonance Health Partners with UK CRO to Include SaMD Services in Global Clinical Trials
Resonance Health signs 24-month deal with UK CRO Image Analysis to add SaMD MRI endpoints to global trials, targeting obesity and metabolic disease.
Patrys Forms Advisory Committee to Guide Development of RLS-2202 Acute Delirium Injectable
Patrys forms international Clinical Advisory Committee to guide RLS-2202 delirium injectable, chaired by Dr Johnny Iliff, ahead of pivotal trials.
Ceretas Completes Key Ultrasound Development Milestone in CUREator+ Cognitive Decline Program
Ceratas completes CUREator+ milestone, unlocking $692k non-dilutive funding; IGN and lift-assist prototypes to cut costs and boost usability.
HeraMED to Deliver HeraCARE Hybrid Maternity Care Solution for Major US Health Network
HeraMED secures US$317k first-phase HeraCARE rollout with Lee Health System, kicking off commercial US expansion via SaaS, Epic EMR integration, 200 patients.
Prescient Therapeutics Advances Lead Asset PTX-100 through Phase 2a Trials as Pharmaceutical Dealmaking Accelerates
Prescient advances PTX-100 in Phase 2a for CTCL; DOC review set for Dec 2026 as Prescient accelerates toward registration data amid booming pharma dealmaking.